2021
Constrained chromatin accessibility in PU.1-mutated agammaglobulinemia patients
Le Coz C, Nguyen DN, Su C, Nolan BE, Albrecht AV, Xhani S, Sun D, Demaree B, Pillarisetti P, Khanna C, Wright F, Chen PA, Yoon S, Stiegler AL, Maurer K, Garifallou JP, Rymaszewski A, Kroft SH, Olson TS, Seif AE, Wertheim G, Grant SFA, Vo LT, Puck JM, Sullivan KE, Routes JM, Zakharova V, Shcherbina A, Mukhina A, Rudy NL, Hurst ACE, Atkinson TP, Boggon TJ, Hakonarson H, Abate AR, Hajjar J, Nicholas SK, Lupski JR, Verbsky J, Chinn IK, Gonzalez MV, Wells AD, Marson A, Poon GMK, Romberg N. Constrained chromatin accessibility in PU.1-mutated agammaglobulinemia patients. Journal Of Experimental Medicine 2021, 218: e20201750. PMID: 33951726, PMCID: PMC8105723, DOI: 10.1084/jem.20201750.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgammaglobulinemiaB-LymphocytesCell DifferentiationCell LineChildChild, PreschoolChromatinDendritic CellsFemaleGene Expression Regulation, DevelopmentalHEK293 CellsHematopoiesisHematopoietic Stem CellsHumansInfantLymphopoiesisMaleMutationPrecursor Cells, B-LymphoidProto-Oncogene ProteinsStem CellsTrans-ActivatorsYoung AdultConceptsPioneer transcription factor PUPro-B cell lineHematopoietic cell fatePre-B cell transitionTranscription factor PUGene expression patternsHuman hematopoietic stemB cell developmentMyeloid cell differentiationBinds target DNAChromatin accessibilityDose-dependent roleCell fateGenomic sitesExpression patternsCell transitionCell developmentCell differentiationHematopoietic stemProgenitor cellsB cellsCell linesAgammaglobulinemia patientsMutationsTarget DNA
2019
Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy
Zammataro L, Lopez S, Bellone S, Pettinella F, Bonazzoli E, Perrone E, Zhao S, Menderes G, Altwerger G, Han C, Zeybek B, Bianchi A, Manzano A, Manara P, Cocco E, Buza N, Hui P, Wong S, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Odicino F, Pecorelli S, Donzelli C, Ardighieri L, Angioli R, Raspagliesi F, Scambia G, Choi J, Dong W, Bilguvar K, Alexandrov LB, Silasi DA, Huang GS, Ratner E, Azodi M, Schwartz PE, Pirazzoli V, Stiegler AL, Boggon TJ, Lifton RP, Schlessinger J, Santin AD. Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy. Proceedings Of The National Academy Of Sciences Of The United States Of America 2019, 116: 22730-22736. PMID: 31624127, PMCID: PMC6842590, DOI: 10.1073/pnas.1911385116.Peer-Reviewed Original ResearchConceptsPI3K/AKT/mTOR pathwaySquamous cell carcinomaWhole-exome sequencingAKT/mTOR pathwayPrimary cervical cancer cell linesPIK3CA inhibitorsRecurrent cervical cancer patientsMTOR pathwayCombination of copanlisibCervical cancer patientsPI3K/Akt/mTORCervical cancer xenograftsRegression of tumorsCervical cancer cell linesCervical tumor cell linesSingle nucleotide variantsWild-type tumorsRecurrent somatic missense mutationsAkt/mTORCell linesPan-HERCancer cell linesTypes 16/18Cervical cancerCancer patientsMutations in ILK, encoding integrin-linked kinase, are associated with arrhythmogenic cardiomyopathy
Brodehl A, Rezazadeh S, Williams T, Munsie NM, Liedtke D, Oh T, Ferrier R, Shen Y, Jones SJM, Stiegler AL, Boggon TJ, Duff HJ, Friedman JM, Gibson WT, Consortium F, Childs SJ, Gerull B. Mutations in ILK, encoding integrin-linked kinase, are associated with arrhythmogenic cardiomyopathy. Translational Research 2019, 208: 15-29. PMID: 30802431, PMCID: PMC7412573, DOI: 10.1016/j.trsl.2019.02.004.Peer-Reviewed Original ResearchConceptsIntegrin-linked kinase geneFirst LIM domainIntegrin-linked kinaseLIM domainsActin cytoskeletonRat myoblast cellsZebrafish showKinase geneCytoplasmic localizationDisease genesArrhythmogenic cardiomyopathyLife-threatening ventricular arrhythmiasMyoblast cellsJunctional proteinsHuman variantsILKSudden cardiac deathGenesFibro-fatty replacementNormal cardiac functionHalf of casesFunctional evidenceHeart muscle disorderMissense variantsDe novo